title: Are human platelet alloantigens (HPA) minor transplantation antigens in clinical bone marrow transplantation?
abstract: The role of human platelet alloantigens (HPA) in clinical bone marrow allotransplantation was investigated. The leading hypothesis was that HPA alloepitopes act as minor histocompatibility antigens and aggravate graft-versus-host disease (GVHD). To exclude the effect of MHC disparity, only HLA identical donor-recipient pairs were entered into the study. The influence of HPA compatibility on overall survival, occurrence of relapses and haematopoietic recovery was also investigated. A total of 223 patients who received a graft from an HLA-identical sibling, genotyped for HPA -1, -2, -3, -4 and -5, were observed over a post-transplant period of 24 months following the protocol recommended by EBMT. The data from patients having received grafts from HPA compatible donors were compared to data from patients having received grafts that were mismatched in HPA allotypes in the GVH direction. Analysis of the incidence of acute and chronic (GVHD), overall survival, relapse incidence, haematopoietic recovery and some other clinical parameters did not reveal any significant difference between the HPA-matched and -mismatched groups of patients, regardless of their age. Our results give no evidence that HPA-1, -2, -3 and -5 alloantigens should be considered minor transplantation antigens in clinical bone marrow transplantation.
authors.affiliation: Blood Transfusion Centre of Slovenia, Ljubljana, Slovenia.
authors.forename: P
authors.initials: P
authors.lastname: Rozman
authors.forename: M
authors.initials: M
authors.lastname: Karas
authors.forename: A
authors.initials: A
authors.lastname: Kosir
authors.forename: B
authors.initials: B
authors.lastname: Labar
authors.forename: A
authors.initials: A
authors.lastname: Madrigal
authors.forename: D
authors.initials: D
authors.lastname: Middleton
authors.forename: C
authors.initials: C
authors.lastname: Navarrete
authors.forename: M
authors.initials: M
authors.lastname: Oudshoorn
authors.forename: H
authors.initials: H
authors.lastname: Schennach
authors.forename: A
authors.initials: A
authors.lastname: Vitek
authors.forename: M
authors.initials: M
authors.lastname: Bohinjec
mesh_terms: D000328:Adult; D016824:Antigens, Human Platelet / Q000235:genetics / Q000276:immunology*; D001792:Blood Platelets / Q000276:immunology*; D016026:Bone Marrow Transplantation / Q000276:immunology*; D005260:Female; D006085:Graft Survival / Q000276:immunology; D006086:Graft vs Host Disease / Q000235:genetics / Q000276:immunology / Q000401:mortality; D006801:Humans; D015994:Incidence; D008297:Male; D008875:Middle Aged; D015778:Minor Histocompatibility Antigens / Q000235:genetics / Q000276:immunology*; D011110:Polymorphism, Genetic; D012008:Recurrence; D015996:Survival Rate
chemical_list: D016824:Antigens, Human Platelet; D015778:Minor Histocompatibility Antigens